How real-time data transformed pharma commercialization

Did you know that 95% of businesses wrestle with unstructured data? 💡At RxPx, we’re tackling this head-on! With our patient-centric approach transforms data into actionable insights for pharmaceutical companies to better understand patient usage and enhance conditions. Our article shares how our Data Insights Team deciphers overwhelming patient data into personalized, meaningful data that is directly tied to achieving positive patient results. 📊 Read the full article here: https://hubs.ly/Q03GmZcR0 #DataInsights #PatientData #HealthcareInnovation

At MMIT (Managed Markets Insight & Technology), we're always looking for new ways to help pharmaceutical manufacturers improve market access and deliver better patient outcomes. I'm thrilled to share that our upcoming release will allow us to enrich claims data by filling in missing BPG details (BIN, PCN, Group) - bringing stronger identification and greater accuracy across the board. Here's what this means for different teams: 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹: Better targeting, cleaner reporting, and deeper access insights 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: Pinpoint a patient's exact plan , speeding time-to-therapy and reducing patient frustration 𝗛𝘂𝗯𝘀 & 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: Minimize mismatches and strengthen payer pull-through strategies This enhancement is a big step forward in connecting the dots across the patient access journey - and I can't wait to see the impact it will have for our partners and, ultimately, for patients. #MMIT #MarketAccess #Pharma #PatientAccess #PharmaStrategy #PayerInsights #FutureofPharma #Norstella #PayerStrategy #PayerData

Most doctors believe interactions with pharma erode public trust, analysis finds. But doctors also said those meetings also have value. https://trib.al/tcYIBBO

In my latest for Geneva Health Files, I examine how MSF’s fight for transparency collided with pharma’s NDAs and what that says about the limits of voluntary accountability in global health.

What does it take to execute a successful #Direct-to-Patient strategy? Hari Ramachandran breaks down the operational realities and dispels common myths surrounding DTP in pharma commercialization. Gain clarity and confidence in your approach. Explore the blog: https://ow.ly/UiWN50WXAR8 #CommercialExcellence #HealthcareDelivery #PharmaInnovation

Hear Ramesh S., Co-Founder and CEO of GenAI Healthcare, speak at the FE Healthcare Summit 2025 about AI's transformative role in empowering doctors, patients, nutritionists, and pharmaceutical companies while driving India towards a technology-led future and shaping the next chapter of healthcare. #FEConnect #ConnectWithFE #AIinHealthcare #DigitalHealth #HealthTech #FutureOfHealthcare

The demand for Power BI in the pharmaceutical industry is skyrocketing. Companies are no longer just collecting data they’re turning it into rich, actionable insights that drive performance. Read more- https://lnkd.in/gyAMEteJ The global healthcare BI market was valued at USD 9.92B in 2024 and is projected to hit USD 31.8B by 2033, growing at a CAGR of 13.9%. Impressive growth but…..it also signals urgency. At Sparity, we accelerate transformation with Power BI. From AI-powered migration tools like BIport to cloud-first architectures designed for pharma compliance, we help healthcare organizations move data from silos to strategy. Book a demo with us - https://lnkd.in/gdDWyWMZ #PowerBI #Pharma #Data #Sparity #Pharmaceutical #BI #BusinessIntelligence

PBMs are the only check against Big Pharma’s pricing power. But PBMs do far more than negotiate rebates. PBMs also improve patient health outcomes, encourage generic drug use, and accelerate the pace of new drug development. The scope of services that PBMs provide equates to creating $145 billion in total value for Americans annually, according to research from the University of Chicago. https://lnkd.in/eMw2KJ-M

🟣 The Purple Cow Strategy: Why "Good Enough" Isn't Enough in Pharma In Seth Godin's Purple Cow framework, being remarkable isn't optional—it's survival. While most companies focus on incremental improvements, true market leaders create something so different that people can't help but talk about it. In the pharmaceutical industry, this means moving beyond: ❌ Me-too formulations ❌ Marginal efficacy improvements ❌ Price-only differentiation ❌ Heavy promotional spending on ordinary products Instead, remarkable pharma companies focus on: ✅ Breakthrough mechanisms of action ✅ Revolutionary delivery systems ✅ Transformative patient experiences ✅ Paradigm-shifting treatment outcomes The purple cow principle in pharma is simple: Your clinical innovation should be so compelling that it markets itself. When physicians can't stop talking about your results, when patients experience life-changing outcomes, when competitors scramble to understand your approach—that's your purple cow moment. The traditional pharma playbook of "good product + big marketing budget" no longer cuts through the noise. In today's evidence-based healthcare environment, remarkable science creates remarkable business results. The question isn't whether you can afford to invest in breakthrough innovation—it's whether you can afford not to be remarkable. What does being "remarkable" mean in your therapeutic area? #PharmaStrategy #Innovation #PurpleCow #Healthcare #MarketingStrategy #Pharma

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: 𝐃𝐚𝐭𝐚-𝐄𝐧𝐫𝐢𝐜𝐡𝐞𝐝 𝐄𝐝𝐢𝐛𝐥𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 (𝐃𝐄𝐄𝐏) The future of patient-tailored therapy is here. DEEP technology enables every oral dose to be customized for the individual—combining precise, digitally adjusted dosing with embedded QR codes for real-time identification, traceability, and patient-specific information. This innovation addresses key industry challenges: limited dose flexibility, medication errors, and supply chain transparency. DEEP also supports sustainability by enabling on-demand, waste-reducing production and seamless integration with digital health platforms. Discover how DEEP is transforming drug discovery, clinical trials, and patient engagement. Are you ready to lead the next wave of pharmaceutical innovation? 👉 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐃𝐄𝐄𝐏 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐩𝐡𝐚𝐫𝐦𝐚:  https://lnkd.in/gG5hkeEf #pharmainnovation #precisionmedicine #digitalhealth #pharmafocusasia #personalizedmedicine #pharmatrends #drugdevelopment #clinicaltrials #patientcentricity #medtech #healthcare #pharma2025 #supplychain #sustainablepharma #regulatorycompliance #futureofpharma #pharmafocus